{"id":37246,"date":"2026-01-27T17:43:11","date_gmt":"2026-01-27T16:43:11","guid":{"rendered":"https:\/\/mabdesign.fr\/?p=37246"},"modified":"2026-01-27T17:43:12","modified_gmt":"2026-01-27T16:43:12","slug":"taconic-biosciences-has-acquired-transcure-bioservices-sas","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/","title":{"rendered":"Taconic Biosciences has acquired TransCure bioServices SAS,"},"content":{"rendered":"\n

Taconic Biosciences has acquired TransCure bioServices<\/a> SAS, giving researchers around the world access to a seamless, end-to-end solution for humanized models, cohort generation, and in vivo studies.

We are uniting Taconic\u2019s global model production and humanized platforms with TransCure\u2019s expertise in translational in vivo pharmacology, CDX and PDX engraftment, and immune profiling\u2014creating a more connected, seamless experience for researchers.

TransCure will continue to operate under its established brand and leadership, ensuring continuity for customers and partners.<\/p>\n\n\n\n


To know more<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Taconic Biosciences has acquired TransCure bioServices SAS, giving researchers around the world access to a seamless, end-to-end solution for humanized models, cohort generation, and in vivo studies.<\/p>\n","protected":false},"author":6,"featured_media":37250,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32,18],"tags":[],"class_list":["post-37246","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members","category-uncategorized"],"yoast_head":"\nTaconic Biosciences has acquired TransCure bioServices SAS, - MabDesign<\/title>\n<meta name=\"description\" content=\"Taconic Biosciences has acquired TransCure bioServices SAS, giving researchers around the world access to a seamless, end-to-end solution for humanized models, cohort generation, and in vivo studies. ImCheck Therapeutics today announced updated results from its Phase I\/II EVICTION study evaluating ICT01, a first-in-class \u03b39\u03b42 T-cell activator, in combination with azacitidine and venetoclax in newly diagnosed AML patients ineligible for intensive chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Taconic Biosciences has acquired TransCure bioServices SAS, - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Taconic Biosciences has acquired TransCure bioServices SAS, giving researchers around the world access to a seamless, end-to-end solution for humanized models, cohort generation, and in vivo studies. ImCheck Therapeutics today announced updated results from its Phase I\/II EVICTION study evaluating ICT01, a first-in-class \u03b39\u03b42 T-cell activator, in combination with azacitidine and venetoclax in newly diagnosed AML patients ineligible for intensive chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-27T16:43:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-27T16:43:12+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/OIP.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"315\" \/>\n\t<meta property=\"og:image:height\" content=\"71\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Maissa Pote\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maissa Pote\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/\"},\"author\":{\"name\":\"Maissa Pote\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029\"},\"headline\":\"Taconic Biosciences has acquired TransCure bioServices SAS,\",\"datePublished\":\"2026-01-27T16:43:11+00:00\",\"dateModified\":\"2026-01-27T16:43:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/\"},\"wordCount\":89,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/OIP.webp\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/\",\"name\":\"Taconic Biosciences has acquired TransCure bioServices SAS, - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/OIP.webp\",\"datePublished\":\"2026-01-27T16:43:11+00:00\",\"dateModified\":\"2026-01-27T16:43:12+00:00\",\"description\":\"Taconic Biosciences has acquired TransCure bioServices SAS, giving researchers around the world access to a seamless, end-to-end solution for humanized models, cohort generation, and in vivo studies. ImCheck Therapeutics today announced updated results from its Phase I\/II EVICTION study evaluating ICT01, a first-in-class \u03b39\u03b42 T-cell activator, in combination with azacitidine and venetoclax in newly diagnosed AML patients ineligible for intensive chemotherapy.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/OIP.webp\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/OIP.webp\",\"width\":315,\"height\":71},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Taconic Biosciences has acquired TransCure bioServices SAS,\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029\",\"name\":\"Maissa Pote\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g\",\"caption\":\"Maissa Pote\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/communication\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Taconic Biosciences has acquired TransCure bioServices SAS, - MabDesign","description":"Taconic Biosciences has acquired TransCure bioServices SAS, giving researchers around the world access to a seamless, end-to-end solution for humanized models, cohort generation, and in vivo studies. ImCheck Therapeutics today announced updated results from its Phase I\/II EVICTION study evaluating ICT01, a first-in-class \u03b39\u03b42 T-cell activator, in combination with azacitidine and venetoclax in newly diagnosed AML patients ineligible for intensive chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/","og_locale":"en_US","og_type":"article","og_title":"Taconic Biosciences has acquired TransCure bioServices SAS, - MabDesign","og_description":"Taconic Biosciences has acquired TransCure bioServices SAS, giving researchers around the world access to a seamless, end-to-end solution for humanized models, cohort generation, and in vivo studies. ImCheck Therapeutics today announced updated results from its Phase I\/II EVICTION study evaluating ICT01, a first-in-class \u03b39\u03b42 T-cell activator, in combination with azacitidine and venetoclax in newly diagnosed AML patients ineligible for intensive chemotherapy.","og_url":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/","og_site_name":"MabDesign","article_published_time":"2026-01-27T16:43:11+00:00","article_modified_time":"2026-01-27T16:43:12+00:00","og_image":[{"width":315,"height":71,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/OIP.webp","type":"image\/webp"}],"author":"Maissa Pote","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Maissa Pote","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/"},"author":{"name":"Maissa Pote","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029"},"headline":"Taconic Biosciences has acquired TransCure bioServices SAS,","datePublished":"2026-01-27T16:43:11+00:00","dateModified":"2026-01-27T16:43:12+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/"},"wordCount":89,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/OIP.webp","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/","url":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/","name":"Taconic Biosciences has acquired TransCure bioServices SAS, - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/OIP.webp","datePublished":"2026-01-27T16:43:11+00:00","dateModified":"2026-01-27T16:43:12+00:00","description":"Taconic Biosciences has acquired TransCure bioServices SAS, giving researchers around the world access to a seamless, end-to-end solution for humanized models, cohort generation, and in vivo studies. ImCheck Therapeutics today announced updated results from its Phase I\/II EVICTION study evaluating ICT01, a first-in-class \u03b39\u03b42 T-cell activator, in combination with azacitidine and venetoclax in newly diagnosed AML patients ineligible for intensive chemotherapy.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/OIP.webp","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/OIP.webp","width":315,"height":71},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/taconic-biosciences-has-acquired-transcure-bioservices-sas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Taconic Biosciences has acquired TransCure bioServices SAS,"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029","name":"Maissa Pote","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g","caption":"Maissa Pote"},"url":"https:\/\/mabdesign.fr\/en\/author\/communication\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=37246"}],"version-history":[{"count":2,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37246\/revisions"}],"predecessor-version":[{"id":37252,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37246\/revisions\/37252"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/37250"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=37246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=37246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=37246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}